Want to see SE:KONT full AI Analyst Report?
Top Page
Kontigo Care AB
(KONT)
Select Model
Select Model
Rating:56Neutral
Price Target:
kr1.50
▼(-16.67% Downside)
Action:Reiterated
Date:10/20/26
The score is driven primarily by improving financial momentum (strong TTM revenue growth) and a low-risk balance sheet with no debt, which support stability. Offsetting this, the company remains loss-making with negative free cash flow, and technical signals show the stock trading below key longer-term moving averages with a negative MACD, limiting near-term attractiveness. Valuation is also constrained by a negative P/E and no stated dividend yield.
Positive Factors
Revenue Reacceleration
The sharp TTM revenue rebound indicates improving demand for Kontigo Care’s solutions and restores growth momentum after the prior decline. If sustained, stronger sales can improve operating leverage, support broader customer adoption, and provide a foundation for eventual profitability.
Negative Factors
Persistent Losses
Continued operating and net losses show that revenue growth has not yet translated into durable earnings. Until profitability becomes consistently positive, Kontigo Care may have less flexibility to fund expansion, absorb setbacks, or demonstrate that its business model scales efficiently.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Reacceleration
The sharp TTM revenue rebound indicates improving demand for Kontigo Care’s solutions and restores growth momentum after the prior decline. If sustained, stronger sales can improve operating leverage, support broader customer adoption, and provide a foundation for eventual profitability.
Read all positive factors
Kontigo Care AB (KONT) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr49.88M
Dividend YieldN/A
Average Volume (3M)21.45K
Price to Earnings (P/E)―
Beta (1Y)-0.14
Revenue Growth0.97%
EPS Growth41.35%
CountrySE
Employees11
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)-0.03
Shares Outstanding35,251,427
10 Day Avg. Volume41,153
30 Day Avg. Volume21,447
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)1.24
Price to Sales (P/S)2.15
P/FCF Ratio-19.36
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)kr43.20M
Kontigo Care AB Business Overview & Revenue Model
Company Description
Kontigo Care AB (publ) specializes in delivering healthcare solutions aimed at addressing addiction issues within Sweden. Their product portfolio includes Previct Alcohol, a digital medical device designed to manage alcohol dependence, and Previct...
How the Company Makes Money
Kontigo Care AB makes money primarily by selling its remote monitoring solutions to organizational customers (e.g., healthcare providers, clinics, municipalities, or other entities running treatment/rehabilitation programs). Revenue is generally g...
Kontigo Care AB Financial Statement Overview
Summary
Income Statement
56
Neutral
Balance Sheet
78
Positive
Cash Flow
52
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 29.56M | 29.13M | 30.24M | 28.95M | 28.43M | 24.54M |
| Gross Profit | 24.89M | 36.56M | 40.08M | 43.73M | 28.24M | 24.16M |
| EBITDA | 5.19M | 3.57M | 5.07M | 1.79M | 4.13M | 90.88K |
| Net Income | -981.00K | -2.07M | 775.00K | 212.00K | 2.90M | -1.20M |
Balance Sheet | ||||||
| Total Assets | 58.49M | 62.12M | 67.74M | 49.77M | 31.39M | 29.20M |
| Cash, Cash Equivalents and Short-Term Investments | 13.24M | 14.95M | 21.86M | 9.85M | 5.74M | 8.48M |
| Total Debt | 0.00 | 0.00 | 3.67M | 5.95M | 0.00 | 1.08K |
| Total Liabilities | 8.79M | 11.62M | 15.42M | 19.05M | 9.98M | 10.74M |
| Stockholders Equity | 49.70M | 50.50M | 52.32M | 30.72M | 21.40M | 18.46M |
Cash Flow | ||||||
| Free Cash Flow | -4.45M | -3.24M | -5.61M | -9.07M | -2.20M | 272.26K |
| Operating Cash Flow | 4.00M | 5.00M | 4.61M | 5.97M | 7.30M | 4.61M |
| Investing Cash Flow | -4.61M | -8.24M | -10.70M | -16.73M | -9.50M | -4.34M |
| Financing Cash Flow | -2.39M | -3.67M | 18.11M | 14.87M | -540.00K | 3.27M |
Kontigo Care AB Technical Analysis
Negative
1.80
Price Trends
1.27
Negative
1.39
Negative
1.52
Negative
Market Momentum
-0.02
Negative
47.19
Neutral
60.79
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:KONT, the sentiment is Negative. The current price of 1.8 is above the 20-day moving average (MA) of 1.19, above the 50-day MA of 1.27, and above the 200-day MA of 1.52, indicating a bearish trend. The MACD of -0.02 indicates Negative momentum. The RSI at 47.19 is Neutral, neither overbought nor oversold. The STOCH value of 60.79 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:KONT.
Kontigo Care AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | kr209.76M | -2.41 | ― | ― | -10.30% | -11.59% | |
58 Neutral | kr450.01M | -93.40 | -3.61% | ― | 15.87% | 92.43% | |
56 Neutral | kr49.88M | -42.41 | -1.94% | ― | 0.97% | 41.35% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | kr440.99M | -3.95 | -37.43% | ― | 27.40% | 26.07% | |
42 Neutral | kr40.91M | -4.18 | 133.94% | ― | -11.53% | -53.21% | |
40 Underperform | kr29.74M | -0.54 | 987.64% | ― | 226.89% | 57.26% |
* Healthcare Sector Average
SE:KONT
Kontigo Care AB
1.42
-0.40
-21.82%
SE:SEZI
Senzime AB
2.81
-3.20
-53.25%
SE:QLIFE
Qlife Holding AB
1.03
-1.04
-50.34%
SE:AINO
Aino Health AB
0.20
0.03
19.05%
SE:MNTC
Mentice AB
16.00
6.38
66.32%
SE:PTRK
Physitrack Limited
12.90
-2.30
-15.13%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.